Home › Brain Tumors › NCT05576103
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
Longitudinal Prospective Study of Neurocognitive Outcomes and Multimodal Quantitative Neuroimaging Outcomes in Primary Brain Tumor Patients Receiving Brain Radiotherapy
Who can join
Ages 18 to 99 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Patients 18 years or older 2. Karnofsky performance status (KPS) ≥70 3. Life expectancy of ≥1 year 4. Primary brain tumor patients who will receive fractionated partial brain RT 5. Able to complete neurocognitive assessments Exclusion Criteria: 1. Inability to undergo MRI with contrast 2. Prior brain RT
About the study
In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through this study to improve understanding of cognitive changes associated with radiation dosage to non-targeted tissue, and will provide the basis for evidence-based cognitive- sparing brain radiotherapy.
Sponsor: Jona Hattangadi-Gluth · Participants: 300 · Started: 2015-01
Contact the study team
- Sheila Medina · Phone: 858-822-6575
Official record on ClinicalTrials.gov — NCT05576103
Locations in the U.S.
| California | Moores Cancer Center, San Diego |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.